Lentiviral vectors (LV) can induce type I interferon (IFN I) production from murine plasmacytoid dendritic cells (pDC), but not myeloid (my)DC. Here, we investigated whether this mechanism is conserved in human DC. MyDC and pDC were isolated from peripheral blood and transduced with increasing vector concentrations. Compared with in vitro differentiated monocyte-derived DC, the transduction efficiency of peripheral blood DC was low (ranging from <1% to 45%), with pDC showing the lowest susceptibility to LV transduction. Phenotype and function of myDC were not directly modified by LV transduction; by contrast, pDC produced significant levels of IFN-α and tumor necrosis factor-α. pDC activation was dependent on functional vector particles and was mediated by Toll-like receptor 7/9 triggering. Coculture of myDC with pDC in the presence of LV resulted in myDC activation, with CD86 up-regulation and interleukin-6 secretion. These findings demonstrate that the induction of transgene-specific immunity is triggered by an innate immune response with pDC activation and consequent myDC maturation, a response that closely resembles the one induced by functional viruses. This information is important to design strategies aimed at using LV in humans for gene therapy, where adverse immune responses must be avoided, or for cancer immunotherapy, where inducing immunity is the goal.
Get full access to this article
View all access options for this article.
References
1.
ArceF., RoweH.M., ChainB., LopesL., CollinsM.K.2009. Lentiviral vectors transduce proliferating dendritic cell precursors leading to persistent antigen presentation and immunization. Mol. Ther., 17:1643–1650.
BarratF.J., MeekerT., GregorioJ., ChanJ.H., UematsuS., AkiraS., ChangB., DuramadO., CoffmanR.L.2005. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med., 202:1131–1139.
4.
BeignonA.S., McKennaK., SkoberneM., ManchesO., DaSilvaI., KavanaghD.G., LarssonM., GorelickR.J., LifsonJ.D., BhardwajN.2005. Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J. Clin. Invest., 115:3265–3275.
5.
BreckpotK., CorthalsJ., HeirmanC., BonehillA., MichielsA., TuyaertsS., De GreefC., ThielemansK.2004. Activation of monocytes via the CD14 receptor leads to the enhanced lentiviral transduction of immature dendritic cells. Hum. Gene Ther., 15:562–573.
6.
BreckpotK., EmeagiP., DullaersM., MichielsA., HeirmanC., ThielemansK.2007. Activation of immature monocyte-derived dendritic cells after transduction with high doses of lentiviral vectors. Hum. Gene Ther., 18:536–546.
BreckpotK., EscorsD., ArceF., LopesL., KarwaczK., Van LintS., KeyaertsM., CollinsM.2010. HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7. J. Virol., 84:5627–5636.
9.
BrownB.D., LillicrapD.2002. Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy. Blood, 100:1133–1140.
10.
BrownB.D., ShiC.X., PowellS., HurlbutD., GrahamF.L., LillicrapD.2004. Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A. Blood, 103:804–810.
11.
BrownB.D., SitiaG., AnnoniA., HaubenE., SergiL.S., ZingaleA., RoncaroloM,G., GuidottiL.G., NaldiniL.2007. In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance. Blood, 109:2797–2805.
12.
CellaM., JarrossayD., FacchettiF., AlebardiO., NakajimaH., LanzavecchiaA., ColonnaM.1999. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med., 5:919–923.
13.
ChenX., HeJ., ChangL.J.2004. Alteration of T cell immunity by lentiviral transduction of human monocyte-derived dendritic cells. Retrovirology, 1:37.
14.
De PalmaM., NaldiniL.2002. Transduction of a gene expression cassette using advanced generation lentiviral vectors. Methods Enzymol., 346:514–529.
15.
Di DomizioJ., BlumA., Gallagher-GambarelliM., MolensJ.P., ChaperotL., PlumasJ.2009. TLR7 stimulation in human plasmacytoid dendritic cells leads to the induction of early IFN-inducible genes in the absence of type I IFN. Blood, 114:1794–1802.
16.
DullaersM., ThielemansK.2006. From pathogen to medicine: HIV-1-derived lentiviral vectors as vehicles for dendritic cell based cancer immunotherapy. J. Gene Med., 8:3–17.
17.
DullaersM., Van MeirvenneS., HeirmanC., StraetmanL., BonehillA., AertsJ.L., ThielemansK., BreckpotK.2006. Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther., 13:630–640.
18.
DyallJ., LatoucheJ.B., SchnellS., SadelainM.2001. Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. Blood, 97:114–121.
19.
FollenziA., SabatinoG., LombardoA., BoccaccioC., NaldiniL.2002. Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum. Gene Ther., 13:243–260.
20.
FollenziA., BattagliaM., LombardoA., AnnoniA., RoncaroloM.G., NaldiniL.2004. Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. Blood, 103:3700–3709.
21.
FonteneauJ.F., LarssonM., BeignonA.S., McKennaK., DaSilvaI., AmaraA., LiuY.J., LifsonJ.D., LittmanD.R., BhardwajN.2004. Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. J. Virol., 78:5223–5232.
22.
GillietM., CaoW., LiuY.J.2008. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol., 8:594–606.
23.
GruberA., Kan-MitchellJ., KuhenK.L., MukaiT., Wong-StaalF.2000. Dendritic cells transduced by multiply deleted HIV-1 vectors exhibit normal phenotypes and functions and elicit an HIV-specific cytotoxic T-lymphocyte response in vitro. Blood, 96:1327–1333.
24.
GuiducciC., OttG., ChanJ.H., DamonE., CalacsanC., MatrayT., LeeK.D., CoffmanR.L., BarratF.J.2006. Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J. Exp. Med., 203:1999–2008.
25.
HeY., ZhangJ., DonahueC., FaloL.D.Jr.2006. Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity, 24:643–656.
26.
HerzogR.W., YangE.Y., CoutoL.B., HagstromJ.N., ElwellD., FieldsP.A., BurtonM., BellingerD.A., ReadM.S., BrinkhousK.M., PodsakoffG.M., NicholsT.C., KurtzmanG.J., HighK.A.1999. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat. Med., 5:56–63.
27.
IwasakiA., MedzhitovR.2004. Toll-like receptor control of the adaptive immune responses. Nat. Immunol., 5:987–995.
28.
KangY., XieL., TranD.T., SteinC.S., HickeyM., DavidsonB.L., McCrayP.B.Jr.2005. Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer. Blood, 106:1552–1558.
29.
KuateS., Stahl-HennigC., StoiberH., NchindaG., FlotoA., FranzM., SauermannU., BredlS., DemlL., IgnatiusR., NorleyS., RaczP., Tenner-RaczK., SteinmanR.M., WagnerR., UberiaK.2006. Immunogenicity and efficacy of immunodeficiency virus-like particles pseudotyped with the G protein of vesicular stomatitis virus. Virology, 351:133–144.
30.
LiuY.J.2005. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu. Rev. Immunol., 23:275–306.
31.
LizeeG., GonzalesM.I., TopalianS.L.2004. Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells. Hum. Gene Ther., 15:393–404.
32.
LopesL., FletcherK., IkedaY., CollinsM.2006. Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy. Cancer Immunol. Immunother., 55:1011–1016.
33.
MannoC.S., PierceG.F., ArrudaV.R., GladerB., RagniM., RaskoJ.J., OzeloM.C., HootsK., BlattP., KonkleB.et al.2006. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med., 12:342–347.
34.
MarsacD., LoiratD., PetitC., SchwartzO., MichelM.L.2002. Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 Gag particles. J. Virol., 76:7544–7553.
35.
MengW.S., ButterfieldL.H.2005. Activation of antigen-presenting cells by DNA delivery vectors. Expert Opin. Biol. Ther., 5:1019–1028.
36.
MountJ.D., HerzogR.W., TillsonD.M., GoodmanS.A., RobinsonN., McClelandM.L., BellingerD., NicholsT.C., ArrudaV.R., LothropC.D.Jr., HighK.A.2002. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood, 99:2670–2676.
37.
NaldiniL., BlomerU., GallayP., OryD., MulliganR., GageF.H., VermaI.M., TronoD.1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science, 272:263–267.
38.
NayakS., HerzogR.W.2010. Progress and prospects: immune responses to viral vectors. Gene Ther., 17:295–304.
39.
PichlmairA., DieboldS.S., GschmeissnerS., TakeuchiY., IkedaY., CollinsM.K., Reis E SousaC.2007. Tubulovesicular structures within vesicular stomatitis virus G protein-pseudotyped lentiviral vector preparations carry DNA and stimulate antiviral responses via Toll-like receptor 9. J. Virol., 81:539–547.
40.
RouasR., UchR., CleuterY., JordierF., BagnisC., MannoniP., LewalleP., MartiatP., Van den BroekeA.2002. Lentiviral-mediated gene delivery in human monocyte-derived dendritic cells: optimized design and procedures for highly efficient transduction compatible with clinical constraints. Cancer Gene Ther., 9:715–724.
41.
RoweH.M., LopesL., IkedaY., BaileyR., BardeI., ZenkeM., ChainB.M., CollinsM.K.2006. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene. Mol. Ther., 13:310–319.
42.
SalmonP., ArrighiJ.F., PiguetV., ChapuisB., ZublerR.H., TronoD., KindlerV.2001. Transduction of CD34+ cells with lentiviral vectors enables the production of large quantities of transgene-expressing immature and mature dendritic cells. J. Gene Med., 3:311–320.
43.
SchroersR., SinhaI., SegallH., Schmidt-WolfI.G., RooneyC.M., BrennerM.K., SuttonR.E., ChenS.Y.2000. Transduction of human PBMC-derived dendritic cells and macrophages by an HIV-1-based lentiviral vector system. Mol. Ther., 1:171–179.
44.
SeedsR.E., GordonS., MillerJ.L.2006. Receptors and ligands involved in viral induction of type I interferon production by plasmacytoid dendritic cells. Immunobiology, 211:525–535.
45.
Smed-SorensenA., LoreK., VasudevanJ., LouderM.K., AnderssonJ., MascolaJ.R., SpetzA.L., KoupR.A.2005. Differential susceptibility to human immunodeficiency virus type 1 infection of myeloid and plasmacytoid dendritic cells. J. Virol., 79:8861–8869.
46.
StarkG.R., KerrI.M., WilliamsB.R., SilvermanR.H., SchreiberR.D.1998. How cells respond to interferons. Annu. Rev. Biochem., 67:227–264.
47.
TanP.H., BeutelspacherS.C., XueS.A., WangY.H., MitchellP., McAlisterJ.C., LarkinD.F., McClureM.O., StaussH.J., RitterM.A., LombardiG., GeorgeA.J.2005. Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy. Blood, 105:3824–3832.
48.
UematsuS., SatoS., YamamotoM., HirotaniT., KatoH., TakeshitaF., MatsudaM., CobanC., IshiiK.J., KawaiT., TakeuchiO., AkiraS.2005. Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha} induction. J. Exp. Med., 201:915–923.
49.
VeronP., BoutinS., BernardJ., DanosO., DavoustJ., MasurierC.2006. Efficient transduction of monocyte- and CD34+-derived Langerhans cells with lentiviral vectors in the absence of phenotypic and functional maturation. J. Gene Med., 8:951–961.
50.
VignaE., NaldiniL.2000. Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J. Gene Med., 2:308–316.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
